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To examine whether weight loss at presentation influences outcome in patients who received chemotherapy for lung cancer or
mesothelioma. Multivariate analysis of prospectively collected data 1994–2001. Data were available for age, gender, performance
status, histology, stage, response, toxicity, progression-free and overall survival. The outcomes of patients with or without weight loss
treated with chemotherapy for small cell lung cancer (SCLC; n¼290), stages III and IV non-small-cell lung cancer (NSCLC; n¼418),
or mesothelioma (n¼72) were compared. Weight loss was reported by 59, 58 and 76% of patients with SCLC, NSCLC and
mesothelioma, respectively. Patients with weight loss and NSCLC (P¼0.003) or mesothelioma (P¼0.05) more frequently failed to
complete at least three cycles of chemotherapy. Anaemia as a toxicity occurred significantly more frequently in NSCLC patients with
weight loss (P¼0.0003). The incidence of other toxicities was not significantly affected by weight loss. NSCLC patients with weight
loss had fewer symptomatic responses (P¼0.001). Mesothelioma patients with weight loss had fewer symptomatic (P¼0.03) and
objective responses (P¼0.05). Weight loss was an independent predictor of shorter overall survival for patients with SCLC
(P¼0.003, relative risk (RR)¼1.5), NSCLC (P¼0.009, RR¼1.33) and mesothelioma (P¼0.03, RR¼1.92) and an independent
predictor of progression-free survival in patients with SCLC (P¼0.01, RR¼1.43). In conclusion, weight loss as a symptom of lung
cancer predicts for toxicity from treatment and shorter survival.
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Lung cancer is the most common cancer globally with more than 1
million new cases recorded each year (Cancer Research Campaign,
2001). Approximately three-quarters of patients have non-small-
cell lung cancer (NSCLC), with small cell lung cancer (SCLC)
accounting for the other quarter. Survival for patients with both
NSCLC and SCLC remains dismal with less than 5% of patients
with NSCLC alive at 5 years and a median survival of 6–10 months
for patients presenting with stage IIIB or IV disease (Cullen et al,
1999; Bonomi et al, 2000; Kelly et al, 2001; Smith et al, 2001).
Similarly, the majority of patients with SCLC die within 18 months
of presentation. Mesothelioma currently accounts for 10000 deaths
worldwide and this number is predicted to increase until at least
2020 (Peto et al, 1995). Survival is poor with a median of between 4
and 18 months in most series.
In patients with lung cancer and mesothelioma, weight loss is
common at presentation and a frequent cause of patient concern.
Weight loss is the result of an imbalance between energy intake
and energy expenditure. Some studies have reported elevated
resting energy expenditure in patients with solid cancers (Fredrix
et al, 1991; Hyltander et al, 1991; Staal-van den Brekel et al, 1994,
1995). It was suggested that this increase is more pronounced in
weight-losing patients and consequently hyper-metabolism con-
tributed to weight loss. However, other studies have not confirmed
such an increase in resting energy expenditure (Melville et al, 1990;
Jatoi et al, 1999). Hyper-metabolism and weight loss have both
been associated with the presence of enhanced levels of
inflammatory mediators and acute phase proteins in NSCLC
(Staal-van den Brekel et al, 1995; Simons et al, 1999). However, it is
not known why only some tumours should result in hyper-
metabolism. Many other factors may contribute to weight loss in
patients with cancer, including nausea and vomiting, constipation,
diarrhoea, pain, altered taste and depression, all of which may be
iatrogenic or due to the cancer.
Several studies have indicated that weight loss at presentation
may be an independent prognostic variable of outcome in both
NSCLC and SCLC (Dewys et al, 1980; Stanley, 1980; Ray et al, 1998;
Martins and Pereira, 1999; Tas et al, 1999), but it has not been
clearly shown why this might be the case. Previous studies have
not addressed whether patients with weight loss have more
aggressive disease than patients without weight loss. An alternative
explanation is that weight loss is associated with reduced tolerance
of chemotherapy, increased toxicity and the administration of less
chemotherapy overall.
The Lung Unit of the Royal Marsden Hospital (RMH) has been
treating patients with NSCLC, SCLC and mesothelioma with
chemotherapy over many years. This study aimed to assess
whether weight loss at presentation had an influence on the
toxicity patients suffered from during chemotherapy, and on
whether weight loss altered the amount of chemotherapy delivered.
In addition, we aimed to assess whether stabilisation of weight
during treatment had any effect on outcome.
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lPATIENTS AND METHODS
Patients
This study reviewed data that had been recorded prospectively on
the RMH lung unit research database between 1994 and March
2001 for patients with SCLC, stage III or IV NSCLC, or
mesothelioma and treated with chemotherapy. Patients were
excluded if their weight loss status at presentation was unknown
or the patient did not receive a standard chemotherapy regimen
within 2 months of presentation. Further exclusion criteria
included prior radiotherapy and prior adjuvant or palliative
chemotherapy. Patients were permitted to have radiotherapy
following chemotherapy, but this variable was not included in
the analysis
Patients who stated they had lost weight at the time of
presentation were compared to those who denied weight loss.
Parameters measured included objective and symptomatic re-
sponse, treatment-related toxicity, progression free and overall
survival. Within the group who had lost weight at presentation,
those with continuing measured weight loss during chemotherapy
were compared with those in whom weight stabilised or increased
during the first 63 days of treatment. The rationale for a 63 day
period for this assessment is that patients treated for NSCLC are
currently treated with three cycles of chemotherapy following the
findings of Smith et al (2001) that survival was similar for patients
treated with three or six cycles of mitomycin, vinblastine and
cisplatin (MVP). Patients were not given dietary advice or
recommended to take dietary supplements.
Patient assessment
Weight loss at presentation was established and recorded by direct
questioning of the patient during a preliminary assessment by the
doctor at their first attendance at the RMH. Patients were asked
whether they had lost any weight since their illness began. Patients
who reported weight loss were asked whether they knew their
weight prior to the illness; by comparison with measured weight
the extent of weight loss was estimated (less than or greater than
10% of preillness weight). Patients were weighed on each
attendance for chemotherapy and at the outpatient clinic.
Objective response to treatment was classified using the WHO/
UICC response criteria following serial CT scans every 6 weeks and
chest X-rays every 3 weeks (WHO, 1979). Symptoms were
established by direct questioning and any change in symptoms
compared to baseline was recorded on each attendance. Response
of a symptom to treatment was defined as improvement in a
particular symptom maintained for at least 3 weeks. Performance
status was recorded at baseline and at each attendance. Toxicity
was graded according to WHO toxicity criteria (WHO, 1979) by
direct questioning, physical examination and measurement of full
blood count, urea and electrolytes, and liver function tests.
Treatment
Chemotherapeutic regimen depended on histology. The majority
of patients treated for NSCLC were treated within the context of
clinical trials with a minimum of three cycles of platinum-
containing regimens, including MVP, carboplatin and vinorelbine,
and docetaxel plus carboplatin (Ellis et al, 1995; Smith et al, 2001).
In addition, 11 patients with NSCLC were treated with single agent
vinorelbine on the basis of the results of the Elderly Lung Cancer
Vinorelbine Italian Study Group (The Elderly Lung Cancer
Vinorelbine Italian Study (ELVIS) Group, 1999). Patients with
SCLC were treated with six cycles of established regimens
(Adriamycin, cyclophosphamide and etoposide; ifosfamide, car-
boplatin and etoposide; carboplatin plus etoposide; MVP) (Smith
et al, 1987, 1990; Jones et al, 1991; Hickish et al, 1998).
Mesothelioma was treated with four cycles of MVP chemotherapy
(Middleton et al, 1998).
Statistical methods
In all analyses the three pathological types were treated
independently. Response rates were compared between the
patients with weight loss at presentation and those without by
means of Fisher’s exact test. Toxicity was graded 0–4 and a
comparison between groups was carried out by means of Mann–
Whitney test with trend. Comparison of the numbers of patients
requiring cessation of treatment or a dose reduction because of
toxicity was made by means of Fisher’s exact test.
Progression free and overall survival from the date of first
treatment and survival curves were generated by the method of
Kaplan and Meier (1958) and compared by means of the log-rank
test (Peto et al, 1976). The multivariate Cox’s proportional hazards
model (Cox, 1972) was used to calculate the relative risk (RR) of
progression or death and to investigate the independent sig-
nificance of prognostic variable. All P-values were two-sided.
RESULTS
Patient characteristics
This study included 780 patients treated by the RMH lung unit
between 1994 and March 2001: 290 with SCLC, 418 NSCLC, and 72
with mesothelioma, with a median age of 63 years (range 27–85
years). In total, 64% of the group were male. There was no
difference in the incidence of weight loss among men (62%)
compared to women (57%; P¼0.2). Patients reported weight loss
more frequently with mesothelioma than with SCLC (P¼0.01) or
NSCLC (P¼0.005) (Table 1).
Effect of weight loss at presentation on chemotherapy-
related toxicity
Overall fewer patients with weight loss (315, 67%) completed three
cycles of chemotherapy than those without weight loss (210, 81%;
Po0.001). This difference was confirmed in patients with NSCLC
(64% vs 78; P¼0.003) (Table 2a) and was due to early disease
progression. In contrast, in patients with SCLC there was no
significant difference in the numbers of patients completing at
least three cycles of chemotherapy (77 vs 84%; P¼0.1) (Table 2a).
Similar numbers of patients stopped treatment due to toxicity in
both groups (P¼0.7; Table 2b). In addition, overall, there were
neither significant differences in frequency of dose reductions
(P¼0.6) nor treatment delays (P¼0.2) according to weight
change. However, treatment was delayed significantly more
frequently in patients with weight loss associated with NSCLC
than those without weight loss (9 vs 4%; P¼0.04)
Patients with NSCLC with weight loss were significantly more
likely to develop severe anaemia as a toxicity than those without
weight loss (P¼0.0003) (Table 3). Anaemia was not more common
in SCLC or mesothelioma patients with weight loss. No differences
in other toxicities from chemotherapy were observed.
Effect of weight loss at presentation on objective and
symptomatic response
There was no relationship between objective response and weight
loss for patients with either SCLC (P¼0.3) or NSCLC (P¼0.5)
(Table 4). There was a lower response rate in patients with
mesothelioma and weight loss (P¼0.05). Patients with NSCLC and
weight loss had significantly more symptoms at presentation than
those without weight loss (Po0.0001) and significantly fewer
symptomatic responses (44 vs 60%; P¼0.004) (Table 4). In
contrast, for patients with SCLC there was neither a correlation
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statistically significant relationship with the frequency of sympto-
matic response (52 vs 64%; P¼0.06). For patients with mesothe-
lioma the number of symptoms is unrelated to weight loss
(P¼0.9), but patients with weight loss reported fewer symptomatic
responses (33 vs 65%; P¼0.03).
Effect of weight loss at presentation on progression-free
survival
At the time of analysis disease progression was documented in 626
(80%) of the 780 patients in the study group, comprising 234 (81%)
patients with SCLC, 336 (80%) patients with NSCLC and 56 (78%)
patients with mesothelioma. All patients were followed up for at
least 1 month and at the time of analysis 650 (83%) of the 780
patients had died. There was reduced progression-free survival in
patients with weight loss and SCLC (6 vs 7 months; P¼0.004) and
with NSCLC (4 vs 6 months; P¼0.01). However, patients with
weight loss and mesothelioma did not have a statistically
significant reduction in progression-free survival (3 vs 6 months;
P¼0.11). Progression-free survival was not statistically different in
patients with weight loss greater than 10% compared to those with
less than 10% weight loss with SCLC and NSCLC (data not shown).
Multivariate analyses were undertaken according to tumour type,
accounting for performance status, disease stage, previous surgery/
radiotherapy and weight loss. Performance status and stage were
the most important prognostic factors for patients with both SCLC
and NSCLC (Table 5). Weight loss resulted in an increased RR of
progression (1.4, 95% confidence intervals 1.0–1.8) for patients
with SCLC. In contrast, weight loss was not a prognostic factor of
progression-free survival for patients with NSCLC. No factors were
significant predictors of progression-free survival in patients with
mesothelioma.
Effect of weight loss at presentation on survival
Overall survival was significantly shorter for patients with weight
loss compared to those without weight loss with SCLC (8 vs 11
months; P¼0.0003), NSCLC (6 vs 9 months; Po0.0001) and
mesothelioma (5 vs 12 months; P¼0.025) (Figure 1A–C). Multi-
variate analysis demonstrated that performance status was
prognostic for patients with SCLC (Po0.001), NSCLC (Po0.001)
and mesothelioma (P¼0.004) (Table 5). In addition, stage was
prognostic for patients with SCLC and NSCLC. Weight loss
remained a prognostic factor for SCLC (RR 1.5, 95% CI 1.0–1.9),
NSCLC (RR 1.3, 95% CI 1.1–1.7) and mesothelioma (RR 1.9, 95%
CI 1.1–3.5). Female gender predicts for improved overall survival
(RR 0.8, 95% CI 0.6–1.0, P¼0.03) and progression-free survival
(RR 0.8, 95% CI 0.6–1.0, P¼0.04) in patients with NSCLC.
Effect of stabilisation of presentation weight loss on
progression-free and overall survival
Data were not available on whether patients with weight loss had
received nutritional intervention of any kind. However, as patients
Table 1 Patient characteristics
Median weight (kg) of patients
without weight loss
Median weight (kg)
of patients with weight loss
Number
of patients
Median age
(range) Male Female
Number
without
weight
loss (%)
Male Female
Number
with weight
loss (%)
Male Female
SCLC 290 65 (38–85) 175 115 119 (41) 77.0 62.0 171 (59) 74.0 57.5
NSCLC 418 62 (27–82) 257 161 174 (42) 77.0 59.5 244 (58) 70.5 55.0
Mesothelioma 72 63 (42–77) 64 8 17 (24) 77.5 56.0 55 (76) 71.0 64.0
Table 2 (a) Completion of at least three cycles of chemotherapy and its
relationship to weight loss, and (b) relationship between cessation of
chemotherapy due to toxicity and weight loss
No weight loss Weight loss
Number Percentage Number Percentage P
(a)
SCLC 100 84 131 77 0.1
NSCLC 135 78 155 64 0.003
Mesothelioma 14 72 29 53 0.05
(b)
All patients 24 8 32 7 0.7
SCLC 3 3 8 5 0.5
NSCLC 18 10 18 7 0.3
Mesothelioma 3 18 6 11 0.4
Table 3 Anaemia induced by MVP chemotherapy and its relationship to weight loss
No weight loss Weight loss No weight loss Weight loss No weight loss Weight loss P
Grade of anaemia toxicity 0 0 1–2 1–2 3–4 3–4
SCLC 33.3% 22.6% 54.8% 62.9% 11.9% 14.5% 0.3
NSCLC 49.7% 35.8% 48.5% 57.8% 1.9% 6.5% 0.0003
Mesothelioma 31.3% 32.1% 68.8% 64.3% 0 3.6 % 0.4
Table 4 Relationship between weight loss and response to chemo-
therapy
Objective response rate (%) Symptom response (%)
No weight
loss
Weight
loss P
No weight
loss
Weight
loss P
SCLC 75 69 0.3 64 52 0.06
NSCLC 37 34 0.5 60 44 0.004
Mesothelioma 29 9 0.05 65 33 0.03
Weight loss and chemotherapy
PJ Ross et al
1907
British Journal of Cancer (2004) 90(10), 1905–1911 & 2004 Cancer Research UK
C
l
i
n
i
c
a
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weight stabilisation were available. Therefore, we examined
whether weight stabilisation during the first 63 days after
presentation in patients who had lost weight at presentation
improved outcome.
Weight was recorded over the first 63 days in 198 of the 470
patients presenting with weight loss. For patients with SCLC weight
stabilisation did not significantly improve progression-free
(P¼0.8) or overall survival (P¼0.95) in comparison to
those who continued losing weight (Figure 2). In contrast, weight
stabilisation for patients with NSCLC resulted in a significant
improvement in both progression-free and overall survival.
Progression-free survival increased from 5 to 7 months
(P¼0.01) and overall survival from 7 to 9 months (P¼0.006)
(Figure 2). Only three patients with mesothelioma had
weight stabilisation during treatment and this did not affect
survival.
DISCUSSION
An important issue for physicians treating patients with lung
cancer and mesothelioma is optimising symptomatic care in view
of the modest survival benefits of cytotoxic chemotherapy. Weight
loss is recognised to occur frequently and has been identified as a
prognostic factor in NSCLC (Dewys et al, 1980; Stanley, 1980;
Hoeltgen et al, 1983), SCLC (Dewys et al, 1980; Wolf et al, 1991;
Bremnes et al, 2003) and mesothelioma (Herndon et al, 1998;
Edwards et al, 2000). In contrast, other studies have not confirmed
weight loss as prognostic for either NSCLC (O’Connell et al, 1986;
Sorensen et al, 1989; Paesmans et al, 1995), SCLC (Paesmans et al,
2000; Christodolou et al, 2002), or mesothelioma (Curran et al,
1998). This study has demonstrated that weight loss at presenta-
tion is an independent prognostic factor for survival of patients’
with NSCLC, SCLC and mesothelioma.
This is the first study to examine the relationship between
weight loss, toxicity, delivery of chemotherapy, response to
treatment and prognosis in patients with lung cancer and
mesothelioma. In NSCLC weight loss is associated with the
delivery of fewer cycles of chemotherapy and more treatment
delays, together with an increased incidence of anaemia as a
toxicity. In addition, weight loss was associated with fewer
symptomatic responses, although there was no significant
difference in the rate of objective response. Furthermore, patients
whose weight stabilised on treatment had significantly better
progression-free and overall survival than those with continued
weight loss. Similarly, in patients with mesothelioma weight loss
was associated with fewer patients completing at least three cycles
of chemotherapy and significantly lower rates of both symptomatic
and objective responses. In contrast, weight loss associated with
SCLC neither affected the number of patients completing at least
three cycles of chemotherapy, the incidence of toxicity nor the
response rate. Moreover, weight stabilisation on treatment neither
improved progression-free nor overall survival. Thus, different
patterns of outcomes were identified for patients with weight loss
associated with NSCLC (and mesothelioma) compared to those
with SCLC.
These differences may be due to differences in the mechanism
of weight loss between the two diseases. Support for this
hypothesis is suggested by a study indicating that weight loss in
SCLC is associated with a greater increase in resting energy
expenditure adjusted for fat-free mass than NSCLC associated
weight loss (Staal-van den Brekel et al, 1997). This suggests
changes in carbohydrate compared with fat metabolism
specifically related to the biology of SCLC. Furthermore, it is
possible that such changes in metabolism may have an adverse
effect on outcomes for patients with SCLC irrespective of
treatment.
Nonetheless, it remains to be demonstrated whether weight loss
is simply a marker of patients with a poor prognosis or whether it
Table 5 Independent factors predictive of progression-free and overall survival in patients with small cell and non-small-cell lung cancer
Progression free survival Overall survival
RR (95% CI) P RR (95% CI) P
SCLC
Stage Limited 1.0 1.0
Extensive 2.0 (1.5–2.6) o0.001 2.4 (18–3.2) o0.001
PS 0 1.0 1.0
1 1.3 (1.1–1.6) o0.001 1.6 (1.3–1.8) o0.001
2 1.8 (1.3–2.5) 2.4 (1.8–3.4)
3 2.4 (1.4–4.1) 3.8 (2.3–6.3)
Weight No loss 1.0 1.0
Loss 1.4 (1.0–1.8) 0.02 1.4 (1.0–1.9) 0.003
NSCLC
PS 0 1.0 1.0
1 1.6 (1.3–2.0) o0.001 1.7 (1.4–2.1) o0.001
2 2.7 (1.9–4.0) 3.2 (2.2–4.5)
3 4.5 (2.5–8.1) 5.6 (3.2–9.6)
Stage III 1.0 1.0
IV 2.0 (1.5–2.4) o0.001 2.0 (1.6–2.5) o0.001
Weight No loss 1.0 1.0
Loss 1.0 (0.9–1.2) 0.4 1.3 (1.1–1.7) 0.009
Mesothelioma
PS 0 1.0
1 1.6 (1.2–2.3) 0.004
2 2.7 (1.4–5.1)
3 4.3 (1.6–11.6)
Weight No loss 1.0
Loss 1.9 (1.1–3.5) 0.03
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lindependently reduces the ability of some patients to be treated
effectively with chemotherapy. The response to chemotherapy may
be altered by weight loss; even a 5% weight loss alters measurable
physiological parameters, such as immune response, lung and
cardiac function tests and autonomic regulation (Jones, 1992). In
the only large group of patients treated with chemotherapy where
the detailed significance of weight loss is known, it has been
demonstrated that weight loss of only 5% at presentation had a
significant adverse effect on survival (Deng et al, 1995). If the latter
were the case it might be predicted that conventional means of
nutritional intervention could be an important adjunct to
treatment. A number of studies have evaluated enteral (Evans
et al, 1987; Ovesen et al., 1993) and parenteral (Klein et al., 1986;
McGeer et al., 1990) nutritional support in patients receiving
treatment for cancer and suggested no benefit from such
interventions. However, these studies were underpowered to
adequately assess the effect. Therefore, a well-designed study to
evaluate the benefit of nutritional support in patients with weight
loss receiving chemotherapy is needed. Given that weight
stabilisation was associated with improved survival in NSCLC,
such a study should be conducted in patients with NSCLC (and
mesothelioma).
The only toxicity that occurred significantly more frequently in
patients with weight loss was anaemia. Intriguingly, we
have previously observed that a nadir haemoglobin level less
than 12gdl
 1 during chemotherapy treatment for SCLC and
NSCLC was associated with poorer survival (Waters et al.,
2002). Thus, the increased incidence of chemotherapy-related
anaemia in patients with weight loss may contribute to the inferior
survival.
Weight loss is an important issue with multivariate analysis
demonstrating an increased risk of death in patients with
SCLC, NSCLC and mesothelioma. In addition, patients with
NSCLC had more symptoms at presentation and in all patients
there was a trend towards reduced symptomatic benefit from
chemotherapy. However, at least for patients with NSCLC
where weight was stabilised, the data suggest a better outcome
can be hoped for. This study emphasises the requirement for
randomised studies of nutritional intervention initially in patients
with NSCLC.
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